Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.
Immunogen Inc (IMGN) is a clinical-stage biotechnology leader pioneering targeted cancer therapies through its proprietary antibody-drug conjugate (ADC) technology. This dedicated news hub provides investors and industry professionals with timely updates on IMGN's scientific advancements, regulatory milestones, and strategic partnerships.
Our curated collection offers immediate access to official press releases, clinical trial developments, and collaboration announcements. Users will find updates on oncology research progress, FDA interactions, and technology licensing agreements that shape IMGN's position in the biopharmaceutical landscape.
Key content types include pipeline advancements for solid tumor treatments, partnership expansions with major pharmaceutical companies, and financial disclosures. The platform serves as a reliable resource for understanding how IMGN's ADC platform addresses complex oncology challenges through precision-targeted therapeutics.
Bookmark this page for streamlined tracking of IMGN's scientific and corporate developments. Combine these updates with Stock Titan's analysis tools to monitor the company's progress in transforming cancer treatment paradigms.
ImmunoGen, Inc. (NASDAQ: IMGN) announced the appointment of Isabel Kalofonos as Senior Vice President and Chief Commercial Officer. This move comes at a pivotal time following the November approval of ELAHERE for platinum-resistant ovarian cancer. CEO Mark Enyedy emphasized Kalofonos's extensive experience in global commercialization will enhance their launch execution and drive ELAHERE's market adoption. Previously, she helped launch a drug at Galderma and led the TAKHZYRO launch at Takeda Pharmaceuticals.
Kalofonos expressed enthusiasm for the role, citing strong physician reception for ELAHERE and the company's ambitions to expand its portfolio. ImmunoGen aims to establish ELAHERE as standard care and broaden its impact in Europe.
ImmunoGen Inc. (NASDAQ: IMGN) announced a conference call scheduled for April 28, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 operating results. The call will also include a business update from management. Interested parties can access the call through registration, and a replay will be available on the company’s website afterward. ImmunoGen specializes in developing antibody-drug conjugates (ADCs) aimed at improving outcomes for cancer patients, focusing on targeted therapies that enhance anti-tumor activity and tolerability.
ImmunoGen, Inc. has secured a term loan financing facility worth